About Opthea Company
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It focuses on treating neovascular age-related macular degeneration and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984, and is headquartered in South Yarra, Australia.
Opthea to Participate at the 2023 Euretina Congress
MELBOURNE, Australia, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, ASX:OPT)), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal
Opthea Completes Retail Entitlement Offer; Shares Fall 3%
Opthea (ASX:OPT) completed the retail component of its 1-for-3.07 nonrenounceable entitlement offer. The retail entitlement offer raised AU$16.3 million, with eligible shareholders taking up about 8.1
Opthea's Options Suspended From Quotation on ASX; Shares Rise 3%
The options of Opthea (ASX:OPT), trading under the ticker OPTOA on the Australian Securities Exchange, will be suspended immediately from quotation on the index, the biopharmaceutical company said Fri